Evidence map›Paper›PMID 35291288›Full record

ReviewRevue francaise d'allergologie (2009)2022

[Biomarkers and functional tests in immediate hypersensitivity to SARS-CoV-2 mRNA vaccines].

P Nicaise-Roland, S Mehlal, C Bouz, S Chollet-Martin

Open access · greenAbstract readEnglish AbstractReview
In one paragraph

Review in Revue francaise d'allergologie (2009), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

P Nicaise-RolandService d'immunologie biologique « Autoimmunité, Hypersensibiltés et Biothérapies », hôpital Bichat, DMU BIOGéM, APHP, 75018 Paris, France.
S MehlalLaboratoire Cerba, Cerba Healthcare, 7/11 rue de l'Equerre, 95310 Saint-Ouen l'Aumône, France.
C BouzLaboratoire Eurofins Biomnis, 17/19, avenue Tony-Garnier, BP 7322, 69357 Lyon cedex 07, France.
S Chollet-MartinService d'immunologie biologique « Autoimmunité, Hypersensibiltés et Biothérapies », hôpital Bichat, DMU BIOGéM, APHP, 75018 Paris, France.
Assistance Publique – Hôpitaux de Paris · FREurofins (France) · FRSaint-Gobain (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypersensitivity to mRNA vaccines directed against SARS-CoV-2 are rare. They may be related to an IgE-dependent mechanism involving PEG contained in vaccines in the form of liposomes. Direct activation of the classical complement pathway (CARPA) has also been strongly suspected. In addition to skin tests, biomarkers have been proposed: anti-PEG antibodies, determination of anaphylatoxins C5a and C3a, or soluble complex C5b-9. Anti-PEG antibodies can be measured by non-standardized in house methods; their presence in post-vaccination reactions against SARS-CoV2 has not been confirmed by all the studies as well as for complement proteins. Mast cell mediators (histamine and tryptase) could rarely be assayed at the time of reaction and their increase is inconstant depending on studies. A slightly elevated baseline tryptase level in some patients suggests that hyper-alphatryptasemia might be involved. A basophil activation test (BAT) can be performed but the results are still preliminary depending on the allergens used: PEG, PEG in the form of liposomes or vaccine itself. The lack of positivity of skin tests in some patients even though basophils are able to be activated in the presence of the same allergen confirms the hypothesis in this case of a possible non-IgE-dependent phenomenon. In conclusion, concerning the exploration of immediate reactions to mRNA vaccines directed against SARS-CoV-2, the place of biological markers requires additional studies in order to better identify the actors and mechanisms involved.

Indexed as

Anti-PEG antibodiesBATC3aC5amRNA vaccinesSARS-CoV-2

Identifiers

PMID35291288
PMCPMC8913372
OpenAlexW4220845685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.